Skip to main content
Premium Trial:

Request an Annual Quote

Caris Dx to Buy Molecular Profiling Institute

NEW YORK (GenomeWeb News) - Caris Diagnostics has agreed to buy Molecular Profiling Institute for an undisclosed sum, Caris said yesterday.
Caris, which has a facility in Tempe, Ariz., said it expects to maintain that presence as well as MPI’s headquarters, which are located in Phoenix.
MPI is a reference lab that offers prognostic testing services and genomic and proteomic profiling for cancer and other complex diseases. Its proprietary offerings include Target Now, a late-stage cancer panel; Mammostrat, an early-stage breast cancer test; and CardioEvaluatR, which is a cardiovascular disease management panel.
MPI also has a Tissue Banking and Analysis Center offering biospecimen procurement, tracking, storage, analysis, and reporting for diagnostics and pharmaceutical companies and medical centers.
"Caris Diagnostics enhances our ability to provide more robust analysis, repository functions, and distribution to patients across the country," MPI CEO Robert Penny said in a statement.
Financial terms of the agreement were not released.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.